Seattle Genetics is a U.S-based biotechnology company that is globally recognized for the positive contributions that it has made to the pharmaceuticals industry. The firm’s current chairman is Clay Siegall who is also its co-founder. He has worked with several researchers in developing targeted cancer cures that have saved the lives of many people across the world. The firm has positively impacted the pharmaceuticals sector through the inventions that it has made. Seattle Genetic is acknowledged for being the first company to develop the antibody-drug conjugates (ADC) technologies that are currently used by many enterprises in developing effective cancer drugs. ADCs are preferred by many doctors since they are safer than chemotherapies.
Under the administration of Clay Siegall, Seattle Technologies has commercialized various drugs that have been developed using the ADC technology, and they include Pfizer, GlaxoSmithKline, Roche, and AbbVie. All these drugs have been licensed by the FDA. Clay had a successful career as biotechnology researcher before the establishment of Seattle Genetics. He was an employee of the National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. Organizations such as Mirna Therapeutics, BioPharmaceuticals, and Ultragenyx believed in his expertise, and they appointed him to serve on the boards. Clay has a genetics Ph.D. from the George Washington University.
The excellent research undertakings of Seattle Genetics have made it easy for medical professionals across the globe to treat cancer patients. Siegall is respected in the pharmaceuticals industry for the excellent work that he has done. He joined Mirna Therapeutics as its external board member in 2013 and has been advising the firm on the development of cures that are based on micro-RNA. Clay currently has 15 patents for different therapies that he has established at Seattle Genetics. He is also an author of various scientific papers and books.
Seattle Genetics started off by depending on support from private and public offerings, but it is currently able to fund itself. The company has more than 21 drugs that are sold across the world. It has to date generated more than $675 million from selling its products. The company is striving to advance its technology, and it will soon commercialize customized cancer treatments.